HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prop 65

This article was originally published in The Tan Sheet

Executive Summary

California bill SB 1572, signed by Gov. Gray Davis Aug. 30, would amend Prop 65 by requiring private litigants settling any alleged violation to submit to the state AG a reporting form that includes results of the settlement, final disposition of the case. Introduced Feb. 20 by Byron Sher (D-Stanford), SB 1572 moved through the legislature without substantive amendment. Measure will supplement added controls on Prop 65 cases recently established by Sher's SB 471, enacted in October 2001. State is in the process of implementing law, which requires private litigants to produce "certificate of merit" demonstrating good cause for seeking Prop 65 warnings (1"The Tan Sheet" May 13, 2002, p. 14)...

You may also be interested in...



Prop 65 Certificate Of Merit Exposure Specificity Urged By CHPA

Certificates of merit filed with private enforcement actions under California's Proposition 65 should include specific details about the alleged toxic exposures, the Consumer Healthcare Products Association says

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel